• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical hypertension. >Telmisartan/Hydrochlorothiazide Combination Therapy for the Treatment of Hypertension: A Pooled Analysis in Older and Younger Patients
【24h】

Telmisartan/Hydrochlorothiazide Combination Therapy for the Treatment of Hypertension: A Pooled Analysis in Older and Younger Patients

机译：替米沙坦/氢氯噻嗪联合治疗高血压：老年和青年患者的汇总分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Older patients frequently receive angiotensin II receptor blocker/diuretic combinations to control blood pressure (BP), although there have been relatively few trials specifically examining this patient population. A pooled analysis was performed of data from 7 randomized trials of telmisartan/hydrochlorothiazide combinations or telmisartan monotherapy in older (65 years and older) and younger (younger than 65 years) patients to better understand the response of older patients to a telmisartan/hydrochlorothiazide combination. Telmisartan doses were 40 mg and 80 mg (T40 and T80). Hydrochlorothiazide doses were 12.5 mg and 25 mg (H12.5 and H25). A total of 3654 patients were included and the mean treatment duration was approximately 8 weeks. BP reductions with telmisartan/hydrochlorothiazide combinations were broadly similar in older and younger patients. In older patients, mean BP reductions from baseline were -30.1/-19.0 mm Hg with the T80/H25 combination and -21.7/-13.0 mm Hg with T80 monotherapy. Tolerability was similar regardless of age, and the incidence of adverse events in both older and younger patients was similar to placebo. The telmisartan/hydrochlorothiazide combination, particularly high-dose T80/H25, is effective and well tolerated in patients 65 years and older as well as in younger patients.
机译：老年患者经常接受血管紧张素II受体阻滞剂/利​​尿剂联合治疗以控制血压（BP），尽管很少有专门检查该患者人群的试验。汇总分析了7例替米沙坦/氢氯噻嗪联用或替米沙坦单药治疗老年患者（65岁及以上）和年轻患者（小于65岁）的随机试验数据，以更好地了解老年患者对替米沙坦/氢氯噻嗪组合的反应。替米沙坦的剂量分别为40 mg和80 mg（T40和T80）。氢氯噻嗪的剂量分别为12.5 mg和25 mg（H12.5和H25）。总共纳入了3654名患者，平均治疗时间约为8周。替米沙坦/氢氯噻嗪联合用药可降低血压，老年患者和年轻患者大致相似。在老年患者中，T80 / H25联合用药的平均血压从基线降低为-30.1 / -19.0 mm Hg，T80单药联合治疗的平均血压降低为-21.7 / -13.0 mm Hg。不论年龄大小，耐受性均相似，并且老年患者和年轻患者中不良事件的发生率与安慰剂相似。替米沙坦/氢氯噻嗪组合，尤其是大剂量的T80 / H25，在65岁以上的患者以及年轻患者中均有效且耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号